SKYSCRAPER-08: A phase III, randomized, double-blind, placebo-controlled study of first-line (1L) tiragolumab (tira) + atezolizumab (atezo) and chemotherapy (CT) in patients (pts) with esophageal squamous cell carcinoma (ESCC).

Journal

Journal of Clinical Oncology

Series/Report No.

Journal of Clinical Oncology

Journal Volume

42

Journal Issue

3_suppl

Start Page

245

End Page

245 - 245

Date Issued

2024-01-01

Author(s)

Lu, Zhihao

Gao, Shegan

Wang, Jun-Ye

Sun, Jong-Mu

Liu, Tianshu

Fan, Qingxia

Cai, Jun

Ge, Feijiao

Li, Sijing

Zhang, Li

Cha, Edward

Shen, Lin

URI

Type

journal article